SCHEMBL20014990

SCHEMBL20014990

Cc1cc(-n2nc3c(c2N)CN(C(=O)OC(C)(C)C)CC3)cc(C)c1Cl

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ F12 P00748 3/20 0.50
▸ C5AR1 P21730 7/20 0.49
▸ ESR2 Q92731 1/20 0.44
▸ NR1H2 P55055 1/20 0.43
▸ ADORA1 P30542 2/20 0.39
▸ MAPT P10636 2/20 0.38
▸ MAP3K14 Q99558 1/20 0.38
▸ PIK3CD O00329 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ PARP1 P09874 1/20 0.36
▸ TNKS2 Q9H2K2 1/20 0.36
▸ PARP2 Q9UGN5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20015142 0.90 F12 (0.50) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL21183650 0.89 F12 (0.52) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL20015371 0.85 F12 (0.50) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL29475107 0.85 F12 (0.50) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL21175127 0.85 F12 (0.35) F12C5AR1
SCHEMBL31692418 0.84 F12 (0.45) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL21725722 0.81 C5AR1 (0.67) F12C5AR1ESR2NR1H2ADORA1
SCHEMBL20014993 0.81 C5AR1 (0.41) F12C5AR1ESR2NR1H2MAPT
SCHEMBL31424521 0.80 C5AR1 (0.45) F12C5AR1NR1H2
SCHEMBL20015355 0.78 NR1H2 (0.33) F12C5AR1ESR2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-04-16 — — US disclosed
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2026-02-26 — — US disclosed
US-12410168-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-09 — — US disclosed
US-12331049-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 — — US disclosed
US-12331050-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-17 — — US disclosed
US-RE50455-E1 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-06-10 — — US disclosed
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-03-20 — — US disclosed
US-12187724-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-01-07 — — US disclosed
US-20250002494-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-01-02 — — US disclosed
US-20240262824-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-08-08 — — US disclosed
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-30 — — US disclosed
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-30 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-14 — — US disclosed
EP-4134367-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-02-15 — — EP disclosed
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-01-21 — — US disclosed
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-12-08 — — US disclosed
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2019-07-25 — — US disclosed
WO-2018056453-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT 中外製薬株式会社 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225604-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-12410168-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20230382912-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-12331049-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20260103463-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 2828/4885C5AR1 1872/4885ESR2 710/4885
US-12187724-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20250002494-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20210017176-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 4372/4885C5AR1 3780/4885ESR2 1608/4885
US-11814381-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 4300/4885C5AR1 3728/4885ESR2 1510/4885
US-20240262824-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20260055105-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GIPR, GPR119 F12 3538/4885C5AR1 3680/4885ESR2 3700/4885
US-12331050-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-10858356-B2 Pyrazolopyridine derivative having GLP-1 receptor agonist effect GLP1R, GPR119, GIPR F12 2777/4885C5AR1 3777/4885ESR2 2170/4885
US-20250092041-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT GLP1R, GPR119, GIPR F12 4300/4885C5AR1 3728/4885ESR2 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback